The present invention relates to an isoxazole derivative compound of Formula (1) useful as a substance for treating respiratory viral infectious disease caused by coronavirus, in particular, Middle East respiratory syndrome-coronavirus (MERS-CoV); a pharmaceutically acceptable derivative thereof; a preparation process of the same; and a pharmaceutical composition for the treatment of coronavirus infection comprising the above comopund as an active ingredient.
本发明涉及一种
异恶唑衍
生物化合物,其
化学式为(1),用作治疗由冠状病毒引起的呼吸道病毒感染疾病,特别是中东呼吸综合征冠状病毒(MERS-CoV)的药物;其药学上可接受的衍
生物;其制备方法;以及一种包含上述化合物作为活性成分的治疗冠状病毒感染的药物组合物。